Rigel Pharmaceuticals Income Statement (2010-2025) | RIGL

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Mar2021	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025
Revenue & cost
Revenue (Quarter)	81.02M	26.27M	21.54M	20.41M	16.73M	29.82M	22.41M	51.28M	26.07M	26.89M	28.13M	35.79M	29.53M	36.84M	55.31M	57.60M	53.33M	101.69M	69.46M	69.80M
Cost of Revenue (Quarter)	0.32M	0.13M	0.15M	0.49M	0.12M	1.04M	0.25M	0.34M	0.98M	1.07M	1.27M	3.79M	2.02M	2.81M	8.03M	5.79M	4.41M	4.50M	4.75M	5.96M
Gross Profit (Quarter)	80.70M	26.14M	21.39M	19.92M	16.61M	28.78M	22.16M	50.94M	25.09M	25.81M	26.87M	32.00M	27.51M	34.03M	47.28M	51.81M	48.92M	97.18M	64.71M	63.85M
Operating items
Research & Development (Quarter)	16.83M	16.81M	18.30M	13.30M	15.47M	14.77M	14.67M	2.50M	10.09M	4.77M	6.47M	3.19M	6.03M	5.54M	6.18M	5.63M	8.44M	6.82M	7.35M	10.69M
Selling, General & Administrative (Quarter)	22.12M	22.38M	22.88M	24.52M	27.40M	26.98M	25.90M	32.17M	27.73M	26.31M	24.86M	26.85M	28.45M	28.05M	27.04M	29.52M	27.71M	29.26M	28.94M	29.99M
Restructuring Costs (Quarter)
Other Operating Expenses (Quarter)	0.32M	0.13M	0.15M	4.01M	0.12M	1.04M	0.25M	14.53M	0.98M	1.07M	1.27M	3.79M	2.02M	2.81M	8.03M	5.79M	4.41M	4.50M	4.75M	5.96M
Operating Expenses (Quarter)	39.26M	39.31M	41.33M	41.83M	43.00M	42.78M	40.81M	49.20M	38.80M	32.15M	32.60M	33.83M	36.50M	36.39M	41.25M	40.94M	40.56M	40.58M	41.04M	46.63M
Operating Income (Quarter)	41.76M	-13.05M	-19.79M	-21.42M	-26.26M	-12.96M	-18.40M	2.08M	-12.72M	-5.27M	-4.46M	1.97M	-6.97M	0.45M	14.06M	16.66M	12.77M	61.10M	28.42M	23.17M
EBIT (Quarter)	41.76M	-13.05M	-19.79M	-21.42M	-26.26M	-12.96M	-18.40M	2.08M	-12.72M	-5.27M	-4.46M	1.97M	-6.97M	0.45M	14.06M	16.66M	12.77M	61.10M	28.42M	23.17M
Non-operating items
Interest & Investment Income (Quarter)	0.00M	0.02M	0.01M	0.02M	0.02M	0.04M	0.19M	0.43M	0.39M	0.53M	0.67M	0.68M	0.59M	0.55M	0.42M	0.52M	0.59M	0.75M	1.09M	1.24M
Net income details
EBT (Quarter)	41.27M	-14.79M	-21.09M	-22.70M	-27.45M	-13.49M	-19.04M	1.40M	-13.54M	-6.60M	-5.69M	0.74M	-8.25M	-1.03M	12.42M	15.22M	11.51M	59.98M	27.62M	22.71M
Tax Provisions (Quarter)	1.77M	-0.97M	-0.10M	-0.10M												0.88M	0.07M	0.37M	-0.28M	-245.35M
Profit After Tax (Quarter)	39.50M	-13.82M	-20.95M	-22.64M	-27.45M	-13.49M	-19.04M	1.40M	-13.54M	-6.60M	-5.69M	0.74M	-8.25M	-1.03M	12.42M	14.34M	11.45M	59.61M	27.90M	268.06M
Income from Continuing Operations (Quarter)	39.50M	-13.82M	-20.99M	-22.61M	-27.45M	-13.49M	-19.04M	1.40M	-13.54M	-6.60M	-5.69M	0.74M	-8.25M	-1.03M	12.42M	14.34M	11.45M	59.61M	27.90M	268.06M
Consolidated Net Income (Quarter)	39.50M	-13.82M	-20.99M	-22.61M	-27.45M	-13.49M	-19.04M	1.40M	-13.54M	-6.60M	-5.69M	0.74M	-8.25M	-1.03M	12.42M	14.34M	11.45M	59.61M	27.90M	268.06M
Income towards Parent Company (Quarter)	39.50M	-13.82M	-20.99M	-22.61M	-27.45M	-13.49M	-19.04M	1.40M	-13.54M	-6.60M	-5.69M	0.74M	-8.25M	-1.03M	12.42M	14.34M	11.45M	59.61M	27.90M	268.06M
Net Income towards Common Stockholders (Quarter)	39.50M	-13.82M	-20.99M	-22.61M	-27.45M	-13.49M	-19.04M	1.40M	-13.54M	-6.60M	-5.69M	0.74M	-8.25M	-1.03M	12.42M	14.34M	11.45M	59.61M	27.90M	268.06M
Additional items
EPS (Basic) (Quarter)	0.23	-0.08	-0.12	-0.14	-0.16	-0.08	-0.11	-3.09	-0.08	-0.38	-0.33	0.05	-0.47	-0.06	0.71	0.81	0.64	3.33	1.55	14.88
EPS (Weighted Average and Diluted) (Quarter)	0.22	-0.08	-0.12	-0.14	-0.16	-0.08	-0.11	-3.09	-0.08	-0.38	-0.33	0.05	-0.47	-0.06	0.70	0.81	0.63	3.28	1.46	14.10
Shares Outstanding (Weighted Average) (Quarter)	169.80M	170.19M	170.30M	170.49M	171.77M	171.96M	172.26M	17.05M	173.57M	17.36M	17.39M	17.40M	17.52M	17.55M	17.60M	17.58M	17.81M	17.85M	17.91M	17.99M
Shares Outstanding (Diluted Average) (Quarter)	176.07M	175.91M	176.45M	170.49M	171.77M	172.15M	172.84M	17.05M	173.57M	17.36M	17.39M	17.40M	17.52M	17.53M	17.65M	17.69M	18.17M	18.16M	19.16M	18.84M
EBITDA (Quarter)	41.76M	-13.05M	-19.79M	-21.42M	-26.26M	-12.96M	-18.40M	2.08M	-12.72M	-5.27M	-4.46M	1.97M	-6.97M	0.45M	14.06M	16.66M	12.77M	61.10M	28.42M	23.17M
Interest Expenses (Quarter)	0.48M	1.76M	1.32M	1.30M	1.21M	0.57M	0.83M	1.11M	1.20M	1.86M	1.90M	1.91M	1.87M	2.03M	2.06M	1.96M	1.85M	1.87M	1.89M	1.70M
Tax Rate (Quarter)	4.29%	6.56%	0.47%	0.42%												5.79%	0.56%	0.62%	-1.01%	-1,080.18%

Research Tools

Rigel Pharmaceuticals Income Statement (2010-2025) | RIGL

Create an account

Sign In

Reset Password